Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing p-coumaric acid and application of composition

A technology of p-coumaric acid and composition, which is applied in the direction of drug combination, medical preparations containing active ingredients, pharmaceutical formulas, etc., to achieve the effect of improving glucose tolerance and insulin resistance

Inactive Publication Date: 2019-06-14
CHINA AGRI UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, in the prior art, the effects of compounding chlorogenic acid and p-coumaric acid to promote body heat production, resist obesity, and improve insulin resistance have not yet been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing p-coumaric acid and application of composition
  • Pharmaceutical composition containing p-coumaric acid and application of composition
  • Pharmaceutical composition containing p-coumaric acid and application of composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1 High-fat and high-sugar diet-induced inhibition verification test of body obesity

[0044] Unless otherwise specified, the C57BL / 6J mice used in the following examples were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.; p-coumaric acid, chlorogenic acid and glucose were chromatographically pure and purchased from Sigma Aldrich (Shanghai) Trading Co., Ltd.; the insulin used is biosynthesized human insulin commercially obtained from formal channels.

[0045] In order to verify the anti-obesity effect of coumaric acid and chlorogenic acid, the present invention fed C57BL / 6J mice with high-fat and high-sugar food. The 4-week-old mice were randomly divided into three experimental groups according to body weight, with 10 mice in each group. The three test groups are:

[0046] Normal grain feeding group (LFD), wherein, the grain energy fed to this group is 3.2kcal / g, contains 4.5% fat, and the drinking water is pure water.

[0047] ...

Embodiment 2

[0052] Example 2 Verification Test of Body's Glucose Tolerance and Insulin Resistance Induced by High Fat and High Sugar Diet

[0053] Obesity is often accompanied by disturbances in glucose homeostasis, resulting in glucose tolerance and insulin resistance. Therefore, the present invention has carried out the following tests to the mice of each test group in the 10th week of administration in embodiment 1:

[0054] 1. Intraperitoneal glucose tolerance test (intraperitoneal glucose tolerance test, IGTT): the mouse after 11 weeks of administration in Example 1 was fasted for 16 hours, and the glucose of 1.5g / kg body weight was injected intraperitoneally after weighing, respectively Blood glucose was measured at 0min, 15min, 30min, 60min, 90min and 120min.

[0055] Such as image 3 As shown, as time goes by after glucose injection, the average blood glucose level of the mice in the HFFD group is higher than that of the mice in the LFD group, while the average blood glucose lev...

Embodiment 3

[0060] Embodiment 3 body heat production test

[0061] The mice treated for the 10th week in Example 1 were placed in room temperature (25° C.) and cold stimulation (4° C.) environments for 3 h respectively, and the body temperature of the mice was measured; the Cooled Incubator / LabMaster (TSE Company) software was used to monitor the consumption of the mice for 24 h. Oxygen.

[0062] The result is as Figure 7 As shown, CA+GCA treatment enhanced body heat production in mice in a cold environment, and was induced by Figure 8 It can be seen that compared with the mice in the HFFD group, CA+GCA treatment increased the oxygen consumption level of the mice by 23.76%, which indicated that CA+GCA treatment enhanced the energy metabolism of the mice, thereby resisting related diseases such as obesity and insulin resistance.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of healthcare products and particularly relates to a pharmaceutical composition containing p-coumaric acid and application of the composition. The effective components of the composition include p-coumaric acid and chlorogenic acid, wherein the mass percentage of the effective components is 0.1-0.8 wt%, and the other component of the composition is a pharmaceutically acceptable carrier. In the effective components, the mass percentage ratio of p-coumaric acid to chlorogenic acid is (4:1)-(1:4). The pharmaceutical composition containing p-coumaric acid is applied to treatment of obesity and related diseases. According to the obtained pharmaceutical composition, the effective components, namely p-coumaric acid and chlorogenic acid, of the pharmaceutical composition can effectively inhibit organism obesity caused by a high-fat and high-sugar diet and improve the glucose tolerance and insulin resistance of the organism, and therefore a new treatment way is provided for treatment of obesity and related diseases.

Description

technical field [0001] The invention belongs to the field of health care products, in particular to a pharmaceutical composition containing p-coumaric acid (CA) and its application in health care products. Background technique [0002] The prevalence of overweight and obesity is increasing worldwide. As of 2015, there were about 107.7 million children and 603.7 million adults worldwide who were obese. Compared with the data in 1980, the prevalence of obesity was 70% doubled in several countries. In my country, obesity is gradually becoming one of the most serious public health problems. In 2015, the overweight rate of Chinese adults was 30.1% (BMI is 24.0-27.9kg / m 2 between), the obesity rate was 11.9% (BMI≥28.0kg / m 2 ). Obesity is a chronic metabolic disease caused by multiple factors, which was included in the list of diseases by the World Health Organization as early as 1948. Numerous epidemiological studies have shown that overweight and obesity have a variety of neg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K31/192A61P3/04A61P5/50
Inventor 黄卫东韩雪郭杰龙游义琳战吉宬
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com